Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-3 of 3
Keywords: Sunitinib
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Oncology
Lothar Bergmann, Viktor Grünwald, Luise Maute, Marc-Oliver Grimm, Steffen Weikert, Jan Schleicher, Theodor Klotz, Jochen Greiner, Anne Flörcken, Arndt Hartmann, Thomas Gauler
Journal:
Oncology Research and Treatment
Oncol Res Treat (2020) 43 (7-8): 333–339.
Published Online: 15 June 2020
... still to be defined. Methods: In this small prospectively randomized phase IIa multicenter trial, we investigated temsirolimus (TEM) versus sunitinib (SUN) as first-line therapy in patients with metastatic nccRCC. The patients were randomized 1:1 to either TEM in a dose of 25 mg i.v. once a week or SUN...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2016) 39 (12): 811–816.
Published Online: 18 November 2016
... up to a dose of 400 mg (orally (p.o.))/day for metastatic disease, and for up to 3 years for adjuvant treatment of high-risk GISTs. Sunitinib can be prescribed and is reimbursed after imatinib failure, and regorafenib has recently become available for routine use. Gastrointestinal stromal tumors...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology Research and Treatment
Oncol Res Treat (2014) 37 (3): 124–126.
Published Online: 26 February 2014
... with metastatic and progressive EHE of the liver. She was successfully treated with daily administration of sunitinib malate, an oral multi-target tyrosine kinase inhibitor, which particularly targets vascular endothelial growth factor (VEGF) receptors. Stabilization has lasted 6 years. We discuss the rationale...